FFA
CRSP icon

Frazier Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Frazier Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$69 – 627
2025
Q1 		$69 Hold
2
– – ﹤0.01% 579
2024
Q4 		$78 Hold
2
– – ﹤0.01% 618
2024
Q3 		$94 Hold
2
– – ﹤0.01% 808
2024
Q2 		$109 Hold
2
– – ﹤0.01% 937
2024
Q1 		$137 Buy
+2
New +$143 ﹤0.01% 880

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Financial Advisors's CRSP Position: Q2 2025 in Review

Frazier Financial Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 2 shares — an estimated $69 sold.

Frazier Financial Advisors first reported a position in CRSP in Q1 2024 and held it in 5 quarters. The position peaked at $137 in Q1 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Frazier Financial Advisors reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Frazier Financial Advisors sold 2 CRISPR Therapeutics shares in Q2 2025, an estimated $69.
  • Frazier Financial Advisors first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 5 quarters.
  • Frazier Financial Advisors's CRISPR Therapeutics position peaked at $137 in Q1 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Frazier Financial Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.